Anti-TFDP3 / Transcription factor Dp family member 3

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. TFDP3 antibody recognizes Transcription factor Dp family member 3, a unique atypical DP protein that modulates E2F-dependent transcription and cell cycle regulation. Unlike canonical DP proteins (TFDP1 and TFDP2), TFDP3 acts as a transcriptional repressor rather than an activator. It binds to E2F transcription factors but lacks the transactivation domain necessary for promoting gene expression, thereby acting as a competitive inhibitor. The TFDP3 antibody is an essential tool for studying cell proliferation, differentiation, apoptosis, and oncogenic transformation regulated through the E2F/DP pathway.TFDP3 is encoded by the TFDP3 gene located on human chromosome Xq26.2. The protein consists of a conserved DNA-binding domain and a dimerization region that facilitates complex formation with E2F1. This heterodimerization blocks the transcriptional activation of E2F target genes involved in DNA synthesis and cell cycle progression. As a result, TFDP3 contributes to cell cycle arrest and resistance to apoptosis, especially under stress or DNA damage conditions.The TFDP3 antibody is used to detect the 45-47 kDa nuclear protein in various cell lines and tissues. Immunofluorescence reveals nuclear localization consistent with its function as a transcriptional regulator. TFDP3 is predominantly expressed in testis, certain stem cells, and a subset of cancer tissues. Its overexpression has been reported in hepatocellular carcinoma, lung adenocarcinoma, and breast cancer, where it promotes survival by suppressing E2F1-induced apoptosis. Mechanistically, TFDP3 interferes with E2F1's ability to induce p53-independent cell death, thereby facilitating oncogenic proliferation.Beyond cell cycle regulation, TFDP3 participates in differentiation processes and developmental gene expression control. It is also implicated in DNA repair regulation and stress-induced transcriptional reprogramming. Studies have shown that silencing TFDP3 enhances the cytotoxic effects of chemotherapeutic agents, making it a potential therapeutic target. NSJ Bioreagents offers a validated TFDP3 antibody optimized for western blot, immunohistochemistry, and chromatin immunoprecipitation, providing researchers with a robust reagent for dissecting E2F pathway regulation and its role in tumor biology.